<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05098678</url>
  </required_header>
  <id_info>
    <org_study_id>64693</org_study_id>
    <nct_id>NCT05098678</nct_id>
  </id_info>
  <brief_title>Zinc Supplementation and Behçet's Syndrome</brief_title>
  <official_title>The Effects of Zinc Gluconate Supplementation on Several Genes Expression, the Serum Level of Inflammatory Factors, Quality of Life, and Disease Activity in Patients With Behcet Syndrome: Double-blind Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tabriz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tabriz University of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effects of zinc gluconate supplementation on patients with Behçet's syndrome, 50&#xD;
      patients will be randomly allocated to two groups: placebo group or zinc group (one tablet of&#xD;
      30 mg/day elemental zinc) for 12 weeks. All participants will be asked not to alter their&#xD;
      diet, medication, and physical activity during the study. At the first and the end of the&#xD;
      intervention, genes and proteins expression, the serum level of inflammatory factors, quality&#xD;
      of life, disease activity, anthropometric measures, physical activity and serum level of zinc&#xD;
      will be assessed and compared between groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 22, 2020</start_date>
  <completion_date type="Actual">September 22, 2021</completion_date>
  <primary_completion_date type="Actual">May 22, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toll-like Receptor-2 gene expression</measure>
    <time_frame>12 weeks</time_frame>
    <description>2-ΔΔCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toll-like Receptor-4 gene expression</measure>
    <time_frame>12 weeks</time_frame>
    <description>2-ΔΔCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toll-like Receptor-2 protein expression</measure>
    <time_frame>12 weeks</time_frame>
    <description>The mean fluorescence intensity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toll-like Receptor-4 protein expression</measure>
    <time_frame>12 weeks</time_frame>
    <description>The mean fluorescence intensity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum level of tumor necrosis factor-alpha</measure>
    <time_frame>12 weeks</time_frame>
    <description>pg/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NLRP3 gene expression</measure>
    <time_frame>12 weeks</time_frame>
    <description>2-ΔΔCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Caspase-1 gene expression</measure>
    <time_frame>12 weeks</time_frame>
    <description>2-ΔΔCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum level of interleukin-1 beta</measure>
    <time_frame>12 weeks</time_frame>
    <description>pg/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum level of zinc</measure>
    <time_frame>12 weeks</time_frame>
    <description>ug/dl</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Behçet's disease quality-of-life</measure>
    <time_frame>12 weeks</time_frame>
    <description>Behçet's disease quality-of-life. The score ranged between 0-30. Zero means high quality of life and 30 means low quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Behcets Disease Activity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Behcet Syndrome</condition>
  <arm_group>
    <arm_group_label>Zinc gluconate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>zinc gluconate tablet daily (120 mg each tablet containing 30 mg elemental zinc)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (microcrystalline cellulose): 1 tablet (120 mg each)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc gluconate</intervention_name>
    <description>120 mg each tablet containing 30 mg elemental zinc</description>
    <arm_group_label>Zinc gluconate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (microcrystalline cellulose): 1 tablet (120 mg each)</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age range 20 to 50 years (premenopausal woman)&#xD;
&#xD;
          -  Diagnosis of Behcet's disease by a rheumatologist according to IBCD (The International&#xD;
             Criteria for Behcet's Disease)&#xD;
&#xD;
          -  Patients who want to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  History of diabetes and other chronic diseases&#xD;
&#xD;
          -  Smoking and alcohol consumption over the past year&#xD;
&#xD;
          -  History of other autoimmune diseases&#xD;
&#xD;
          -  Consumption of nutritional and antioxidant supplements over two months prior to the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tabriz University of Medical Sciences</name>
      <address>
        <city>Tabriz</city>
        <state>East Azerbaijan</state>
        <zip>5166614756</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tabriz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Beitullah Alipour</investigator_full_name>
    <investigator_title>Beitullah Alipour, Ph.D., Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behcet Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

